This Article  • Full text  • PDF  • Correction  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (63)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Randomized Controlled Trial  • Alert me on articles by topic

A Meta-analysis of Randomized Controlled Trials

Lydia A. Bazzano, MD, PhD; Kristi Reynolds, PhD; Kevin N. Holder, MD; Jiang He, MD, PhD

JAMA. 2006;296:2720-2726.

Context  Epidemiologic studies have suggested that folate intake decreases risk of cardiovascular diseases. However, the results of randomized controlled trials on dietary supplementation with folic acid to date have been inconsistent.

Objective  To evaluate the effects of folic acid supplementation on risk of cardiovascular diseases and all-cause mortality in randomized controlled trials among persons with preexisting cardiovascular or renal disease.

Data Sources  Studies were retrieved by searching MEDLINE (January 1966-July 2006) using the Medical Subject Headings cardiovascular disease, coronary disease, coronary thrombosis, myocardial ischemia, coronary stenosis, coronary restenosis, cerebrovascular accident, randomized controlled trial, clinical trials, homofolic acid, and folic acid, and the text words folic acid and folate. Bibliographies of all retrieved articles were also searched, and experts in the field were contacted.

Study Selection  From 165 relevant retrieved reports, 12 randomized controlled trials compared folic acid supplementation with either placebo or usual care for a minimum duration of 6 months and with clinical cardiovascular disease events reported as an end point.

Data Extraction  Data on study design, characteristics of participants, changes in homocysteine levels, and cardiovascular disease outcomes were independently abstracted by 2 investigators using a standardized protocol.

Data Synthesis  Studies including data from 16 958 participants with preexisting vascular disease were analyzed using a random-effects model. The overall relative risks (95% confidence intervals) of outcomes for patients treated with folic acid supplementation compared with controls were 0.95 (0.88-1.03) for cardiovascular diseases, 1.04 (0.92-1.17) for coronary heart disease, 0.86 (0.71-1.04) for stroke, and 0.96 (0.88-1.04) for all-cause mortality. The relative risk was consistent among participants with preexisting cardiovascular or renal disease.

Conclusions  Folic acid supplementation has not been shown to reduce risk of cardiovascular diseases or all-cause mortality among participants with prior history of vascular disease. Several ongoing trials with large sample sizes might provide a definitive answer to this important clinical and public health question.

Author Affiliations: Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine (Drs Bazzano, Reynolds, and He); and Department of Medicine, Tulane University School of Medicine (Drs Bazzano, Holder, and He), New Orleans, La.

RELATED LETTERS

Folic Acid Supplementation and Cardiovascular Diseases
Suhal S. Mahid, Kyle S. Minor, and Susan Galandiuk
JAMA. 2007;297(14):1549.
EXTRACT | FULL TEXT  

Folic Acid Supplementation and Cardiovascular Diseases
Francesco Dentali, Monica Gianni, and Walter Ageno
JAMA. 2007;297(14):1549-1550.
EXTRACT | FULL TEXT  

Folic Acid Supplementation and Cardiovascular Diseases—Reply
Lydia A. Bazzano, Kristi Reynolds, Kevin N. Holder, and Jiang He
JAMA. 2007;297(14):1550.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Folic Acid
John L. Zeller, Alison E. Burke, and Richard M. Glass
JAMA. 2006;296(22):2758.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Did national folic acid fortification reduce socioeconomic and racial disparities in folate status in the US?
Dowd and Aiello
Int J Epidemiol 2008;37:1059-1066.
ABSTRACT | FULL TEXT  

Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
Ebbing et al.
JAMA 2008;300:795-804.
ABSTRACT | FULL TEXT  

Plasma total homocysteine: instigator or indicator of cardiovascular disease?
Moat
Ann Clin Biochem 2008;45:345-348.
ABSTRACT | FULL TEXT  

The prevalence of folate-remedial MTHFR enzyme variants in humans
Marini et al.
Proc. Natl. Acad. Sci. USA 2008;105:8055-8060.
ABSTRACT | FULL TEXT  

Lifestyle and Risk of Cardiovascular Disease and Type 2 Diabetes in Women: A Review of the Epidemiologic Evidence
Bassuk and Manson
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:191-213.
ABSTRACT  

Economic evaluation of folic acid food fortification in The Netherlands
Jentink et al.
Eur J Public Health 2008;18:270-274.
ABSTRACT | FULL TEXT  

Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management
Sudlow
PN 2008;8:141-157.
ABSTRACT | FULL TEXT  

Plasma Homocysteine, but Not Folate or Vitamin B-12, Predicts Mortality in Older People in the United Kingdom
Dangour et al.
J. Nutr. 2008;138:1121-1128.
ABSTRACT | FULL TEXT  

Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality Among Women at High Risk for Cardiovascular Disease: A Randomized Trial
Albert et al.
JAMA 2008;299:2027-2036.
ABSTRACT | FULL TEXT  

Trends in Circulating Concentrations of Total Homocysteine among US Adolescents and Adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys
Pfeiffer et al.
Clin. Chem. 2008;54:801-813.
ABSTRACT | FULL TEXT  

Folate, Vitamin B6, Vitamin B12, and Methionine Intakes and Risk of Stroke Subtypes in Male Smokers
Larsson et al.
Am J Epidemiol 2008;167:954-961.
ABSTRACT | FULL TEXT  

Homocysteine, vitamins, and vascular disease prevention: more negative results
Soliman and Shalash
Am. J. Clin. Nutr. 2008;87:1069-1070.
FULL TEXT  

Reply to EZ Soliman and OA Shalash
McCully
Am. J. Clin. Nutr. 2008;87:1070-1071.
FULL TEXT  

Reply
Baragetti et al.
Nephrol Dial Transplant 2008;23:1069-1071.
FULL TEXT  

Hyperhomocysteinaemia and endothelial dysfunction in dialysis patients: what should be treated first?
Righetti
Nephrol Dial Transplant 2008;23:1069-1069.
FULL TEXT  

Update in Geriatric Medicine
Reuben
ANN INTERN MED 2007;147:470-477.
FULL TEXT  

Evidently...
Lehman
Evid. Based Med. 2007;12:135-135.
FULL TEXT  

B Vitamins for the Prevention of Vascular Disease: Insufficient Evidence to Justify Treatment
Baigent and Clarke
JAMA 2007;298:1212-1214.
FULL TEXT  

Trends in blood folate and vitamin B-12 concentrations in the United States, 1988 2004
Pfeiffer et al.
Am. J. Clin. Nutr. 2007;86:718-727.
ABSTRACT | FULL TEXT  

Folate and Cancer--Timing Is Everything
Ulrich and Potter
JAMA 2007;297:2408-2409.
FULL TEXT  

Homocysteine and Cardiovascular Risk: Considering the Evidence in the Context of Study Design, Folate Fortification, and Statistical Power
Ueland and Clarke
Clin. Chem. 2007;53:807-809.
FULL TEXT  

From the Library
Br. J. Ophthalmol. 2007;91:704-704.
FULL TEXT  

Folic Acid Supplementation and Cardiovascular Diseases
Mahid et al.
JAMA 2007;297:1549-1549.
FULL TEXT  

Folic Acid Supplementation and Cardiovascular Diseases
Dentali et al.
JAMA 2007;297:1549-1550.
FULL TEXT  

Folic Acid Doesn't Prevent Heart Disease
Kerr
DOC News 2007;4:1-9.
FULL TEXT  

JournalScan
Lindsay
Heart 2007;93:536-538.
FULL TEXT  

No Secondary-Prevention Benefit of Folic Acid
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT  

Folic acid fails to protect against cardiovascular disease
BMJ 2006;333:1266-1266.
FULL TEXT